Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 9,025 shares, a decrease of 31.5% from the January 29th total of 13,176 shares. Based on an average daily volume of 49,744 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 49,744 shares, the days-to-cover ratio is currently 0.2 days.

Fresenius SE & Co. Trading Down 0.7%

Fresenius SE & Co. stock traded down $0.11 during trading on Friday, hitting $15.10. The company had a trading volume of 140,780 shares, compared to its average volume of 26,812. The stock has a market cap of $34.02 billion, a price-to-earnings ratio of 23.97 and a beta of 0.75. The company has a current ratio of 1.26, a quick ratio of 0.99 and a debt-to-equity ratio of 0.49. Fresenius SE & Co. has a 1-year low of $9.78 and a 1-year high of $33.93. The company’s 50 day simple moving average is $14.60 and its 200-day simple moving average is $14.43.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.28 EPS for the quarter. Fresenius SE & Co. had a return on equity of 10.38% and a net margin of 5.71%.The business had revenue of $6.94 billion during the quarter. As a group, analysts expect that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

FSNUY has been the subject of several recent analyst reports. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.